Vivacelle Bio, Inc. - VBI

2 Phase IIa-Ready IV phospholipid nanoparticle fluids to treat hypovolemic shock due to blood loss & sepsis. $43 billion market,quick FDA pathway. Patents.

  • Stage Full Product Ready
  • Industry Biotechnology
  • Location Chicago, IL, US
  • Currency USD
  • Founded August 2013
  • Employees 5
  • Incorporation Type C-corp
  • Website vivacellebio.com

Company Summary

VBI-1 and VBI-S injectable phospholipids to sustain life after hypovolemia due to blood loss & sepsis. Other products are toxic/more expensive. FDA granted clearance to initiate phase IIa clinical trials using VBI-1 & VBI-S to treat hypovolemia due to blood loss & sepsis & CV-19 compassionate use. Preclinical studies show safety, efficacy & protection from reperfusion injury. ~$43 billion addressable market. POC in 2 human patients for VBI-S.

Team

  • Founder, President and Chief Innovation Officer

    Dr. Simpkins is the inventor of Vivacelle. He is also a trauma surgeon and scientist with over thirty years of experience including serving as Director of the Trauma Program at LSU Health Sciences Center in Shreveport, LA. He achieved the rank of Commander and received two commendations for excellence in research while serving in the U.S. Navy which included several scientific discoveries and publications. MD- Harvard, BA-Amherst College

  • Chief Executive Officer

    Dr. DeShield, former CLO and COO of VBI, is a pharma. & life sciences IP attorney with more than 11 years experience. Well-versed in start up fund raising, patent litigation and prosecution, licensing and assignments of patents & trademarks, RSPAs, M&A, FDA law, commercialization & Business Dev., contracts & business agreements. Former, VP, BD/Commercialization of med. device company. Doctorate in Biochemistry & Masters in Biological Sciences.

  • Chief Medical Officer

    Dr.. Talluri is the owner of Compass Consulting International. She has over eighteen years of experience in drug development and medical affairs including stints at Johnson & Johnson, CATO, Lundbeck and Talecris Biotherapeutics. Her experience includes successful IND's and NDA's in CNS, neuroimmunology, immunology, pulmonary, oncology and other indications. Psychiatry Residency- Duke University Emergency Medicine-St. Lucia

  • Mukesh Kumar, Ph. D.
    Senior Vice President, Regulatory Affairs

    Dr Kumar is a Ph. D. Biochemist with more than 20 years experience in Clinical Development and Regulatory Professional, Inventor on multiple patents & a Former NIH Staff Scientist. He has written more than 40 new INDs for FDA submission & reviewed more than 100 INDs. Dr. Kumar has been involved in about 100 clinical trials in more than 40 countries, has made several hundred US FDA submissions, and arranged a number of meetings with the US FDA.

Advisors

  • Thomas Fitzgerald M.B.A.
    Unconfirmed

Previous Investors

  • Ron Damper
    Unconfirmed

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free